Core Viewpoint - Beihai Kangcheng-B (01228) experienced a significant stock price increase, rising nearly 18% during trading, with a current increase of 11.76% to HKD 2.09, and a trading volume of HKD 10.2188 million [1] Group 1: Company Developments - The details of the "Beijing Universal Health Insurance" for the year 2026 have recently been announced, with three rare disease products from Beihai Kangcheng included [1] - The drug Goreni, which was approved for market on May 13 this year, made its debut in the "Universal Health Insurance" [1] - Goreni was first prescribed at the Xinhua Hospital affiliated with Shanghai Jiao Tong University School of Medicine on July 2, marking its official entry into clinical application, which is expected to significantly enhance drug accessibility for domestic patients [1]
北海康成-B盘中涨近18% 旗下三款罕见病产品均纳入2026年度北京普惠健康保